# Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

> **NCT06081595** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jin Li** · enrollment: 54 (estimated)

## Conditions studied

- Relapsed Ovarian Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT06081595
- **Lead sponsor:** Jin Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-10-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2023-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081595, "Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06081595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*